Granules India Limited

54.2%

9 , 9 0 0 3 , 0 1 6 9 1 , 0 1 8 9 4 , 8 3 8 8 , 8 9 3 0 , 5 0 6 0 , 5 7 0 6 , 4 7 1 5 , 4 54.2% 50.9% 8 4 6 , 4 46.6% 48.9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5

50.9%

0 0 3 , 0 1 6 9 1 , 0 1 8 9 4 , 8 3 8 8 , 8 9 3 0 , 5 0 6 0 , 5 7 0 6 , 4 7 1 5 , 4 54.2% 50.9% 8 4 6 , 4 46.6% 48.9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5 1 1 ,

46.6%

1 , 0 1 8 9 4 , 8 3 8 8 , 8 9 3 0 , 5 0 6 0 , 5 7 0 6 , 4 7 1 5 , 4 54.2% 50.9% 8 4 6 , 4 46.6% 48.9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5 1 1 , 2 7 2 9 , 1 20.

48.9%

1 8 9 4 , 8 3 8 8 , 8 9 3 0 , 5 0 6 0 , 5 7 0 6 , 4 7 1 5 , 4 54.2% 50.9% 8 4 6 , 4 46.6% 48.9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5 1 1 , 2 7 2 9 , 1 20.7% 18

49.6%

9 4 , 8 3 8 8 , 8 9 3 0 , 5 0 6 0 , 5 7 0 6 , 4 7 1 5 , 4 54.2% 50.9% 8 4 6 , 4 46.6% 48.9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5 1 1 , 2 7 2 9 , 1 20.7% 18.7% 1

23.7%

9 3 0 , 5 0 6 0 , 5 7 0 6 , 4 7 1 5 , 4 54.2% 50.9% 8 4 6 , 4 46.6% 48.9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5 1 1 , 2 7 2 9 , 1 20.7% 18.7% 17.4% Q1FY22 Q2FY2

17.0%

, 4 7 1 5 , 4 54.2% 50.9% 8 4 6 , 4 46.6% 48.9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5 1 1 , 2 7 2 9 , 1 20.7% 18.7% 17.4% Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY2

17.4%

1 5 , 4 54.2% 50.9% 8 4 6 , 4 46.6% 48.9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5 1 1 , 2 7 2 9 , 1 20.7% 18.7% 17.4% Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY2

25.1%

4 54.2% 50.9% 8 4 6 , 4 46.6% 48.9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5 1 1 , 2 7 2 9 , 1 20.7% 18.7% 17.4% Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY2

20.7%

.6% 48.9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5 1 1 , 2 7 2 9 , 1 20.7% 18.7% 17.4% Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY2

18.7%

9% 49.6% 4 1 0 , 2 23.7% 7 3 7 , 1 2 1 5 , 1 17.0% 17.4% 25.1% 5 1 1 , 2 7 2 9 , 1 20.7% 18.7% 17.4% Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY2

21%

(In ₹ Mn) Growth in Europe due to higher Paracetamol sales Finished Dosage and PFI segments grew 21% and 38% Q1FY22 5.4% i x M 13.8% Q1FY23 6.5% 8.1% l i a c h p a r g o e G 10.9% 16.8% US

As Encl

1

Total GPI products include

1

Corporate address

1

As Encl

Granules India Limited Q1FY23 Earnings Presentation 1 Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from

Total GPI products include

ANDA/Dossier filed - Therapeutic area wise CII – 7 PFOS – 4 Liquid Orals – 3 Analgesics Central Nervous System Anti-diabetics Mineral supplements 5 Cardiovasculars Anti Histamines 4 Anti gout Antitussives Other areas 3 3 8 7 22 18 12 7 Revenue trend – percentage share from Core and Other Molecules Core Others Para MF IBU GGF MCB Others 14% 14% 17% 14% 15% 17% 16% 15% 19% 16% 86% 86% 83% 86% 85% 83% 84% 85% 81% 84% 14% 34% 1% 5% 17% 29% 33% 17% 26% 6% 4% 19% 21% 21% 34% 29% 34% 34% 33% 30% 15% 18% 5% 3% 25% 19% 23% 17% 29% 14% 16% 3% 3% 3% 18% 16% 19% 3% 3% 13% 3% 6% 26% 25% 17% 4% 5% 5% 1% 14% 34% 38% 3% 14% FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Core includes Paracetamol, Metformin, Ibuprofen, Methocarbamol and Guaifenesin 8 5-year trajectory: Key Ratios and Cash Flow (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow (FCF) 9,082 8,704 3.1 6,138 2.1 6,058 5,752 2.4 6,966 135 125 138 114 109 117 2,919 1,615 1.2 1.0 0.7 Mar-17 Mar-18 Mar-19 M

Corporate address

Floor 2 Block 3 My Home Hub Madhapur Hyderabad 500081 CIN: L24110TG1991PLC012471 Voice: +91 40 69043600 Fax: +91 40 69043602 www.granulesindia.com 532482 GRANULES GRAN:IN GRAN:NS